Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
Active, not recruiting · NCT05176002 · Registry updated 2025-11-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal disorder, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2025-11-19 | NCT05176002 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fujian Medical University Union Hospital | 108 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fujian Medical University Union Hospital | Fuzhou | China | 107 |